| Item Type |
Article |
| ID |
|
| Preview |
| Image |
|
| Caption |
|
|
| Full text |
KAKEN_17H04306seika.pdf
| Type |
:application/pdf |
Download
|
| Size |
:234.8 KB
|
| Last updated |
:Mar 5, 2021 |
| Downloads |
: 197 |
Total downloads since Mar 5, 2021 : 197
|
|
| Release Date |
|
| Title |
| Title |
悪性神経膠腫に対する革新的ワクチン療法の開発
|
| Kana |
アクセイ シンケイ コウシュ ニ タイスル カクシンテキ ワクチン リョウホウ ノ カイハツ
|
| Romanization |
Akusei shinkei kōshu ni taisuru kakushinteki wakuchin ryōhō no kaihatsu
|
|
| Other Title |
| Title |
Development of novel vaccine immunotherapy for malignant glioma
|
| Kana |
|
| Romanization |
|
|
| Creator |
| Name |
戸田, 正博
 |
| Kana |
トダ, マサヒロ
|
| Romanization |
Toda, Masahiro
|
| Affiliation |
慶應義塾大学・医学部 (信濃町) ・准教授
|
| Affiliation (Translated) |
|
| Role |
Research team head
|
| Link |
科研費研究者番号 : 20217508
|
|
| Edition |
|
| Place |
|
| Publisher |
|
| Date |
| Issued (from:yyyy) |
2020
|
| Issued (to:yyyy) |
|
| Created (yyyy-mm-dd) |
|
| Updated (yyyy-mm-dd) |
|
| Captured (yyyy-mm-dd) |
|
|
| Physical description |
|
| Source Title |
| Name |
科学研究費補助金研究成果報告書
|
| Name (Translated) |
|
| Volume |
|
| Issue |
|
| Year |
2019
|
| Month |
|
| Start page |
|
| End page |
|
|
| ISSN |
|
| ISBN |
|
| DOI |
|
| URI |
|
| JaLCDOI |
|
| NII Article ID |
|
| Ichushi ID |
|
| Other ID |
|
| Doctoral dissertation |
| Dissertation Number |
|
| Date of granted |
|
| Degree name |
|
| Degree grantor |
|
|
| Abstract |
マウスグリオーマ細胞株で同定したNeoangtigenを標的とするエピトープペプチドと抗PD-1抗体を組み合わせた複合免疫療法に、VEGFR1/VEGFR2を標的とするエピトープペプチドを上乗せすることで、腫瘍細胞、血管内皮、さらに免疫抑制性の制御性T細胞を統合的に標的とし、著明な生存期間の延長に成功した。さらにマウスBTSC株には特にVEGFR2が高発現することを見出し、同様の複合免疫療法で生存期間は延長した。また得られた治療後の組織変化を、実際にVEGFRsワクチン療法が為された悪性神経膠腫患者検体でも確認し、本複合免疫療法の治療効果の根拠を確立することができた。
In the present study, we established a novel combinational immunotherapy using epitope peptide targeting glioma neoantigen and vascular endothelial growth factor receptor (VEGFR)1/2, and anti-programmed cell death (PD)-1. Induced cytotoxic T lymphocytes could kill not only tumor vessel cells but also tumor cells and immunosuppressive regulatory T cells (Tregs) expressing VEGFRs. Remarkable prolonged survival was achieved in the glioma mouse model. Furthermore, we revealed that VEGFR2 is highly expressed in the glioma stem cells (GSCs). This approach could inhibit the proliferation of GSCs in an orthotopic mouse model. The histopathological findings of pre- and post-VEGFRs vaccination glioblastoma specimens demonstrated that more apoptosis was detected in tumor cells, and the number of Foxp3-positive cells decreased after vaccination.
This novel immunotherapy targeting a large variety of cells has the possibility to show higher treatment efficacy for the patients with malignant glioma.
|
|
| Table of contents |
|
| Keyword |
|
| NDC |
|
| Note |
研究種目 : 基盤研究 (B) (一般)
研究期間 : 2017～2019
課題番号 : 17H04306
研究分野 : 脳神経外科学
|
|
| Language |
|
| Type of resource |
|
| Genre |
|
| Text version |
|
| Related DOI |
|
| Access conditions |
|
| Last modified date |
|
| Creation date |
|
| Registerd by |
|
| History |
|
| Index |
|
| Related to |
|
